tiprankstipranks
Trending News
More News >
Glenmark Pharmaceuticals Limited (IN:GLENMARK)
:GLENMARK
India Market
Advertisement

Glenmark Pharmaceuticals Limited (GLENMARK) Price & Analysis

Compare
1 Followers

GLENMARK Stock Chart & Stats


Financials

GLENMARK FAQ

What was Glenmark Pharmaceuticals Limited’s price range in the past 12 months?
Glenmark Pharmaceuticals Limited lowest stock price was ₹1274.70 and its highest was ₹2286.15 in the past 12 months.
    What is Glenmark Pharmaceuticals Limited’s market cap?
    Glenmark Pharmaceuticals Limited’s market cap is ₹621.66B.
      When is Glenmark Pharmaceuticals Limited’s upcoming earnings report date?
      Glenmark Pharmaceuticals Limited’s upcoming earnings report date is Aug 08, 2025 which is in 20 days.
        How were Glenmark Pharmaceuticals Limited’s earnings last quarter?
        Glenmark Pharmaceuticals Limited released its earnings results on May 23, 2025. The company reported ₹10.1 earnings per share for the quarter, missing the consensus estimate of ₹12.1 by -₹2.
          Is Glenmark Pharmaceuticals Limited overvalued?
          According to Wall Street analysts Glenmark Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Glenmark Pharmaceuticals Limited pay dividends?
            Glenmark Pharmaceuticals Limited pays a Annually dividend of ₹2.5 which represents an annual dividend yield of 0.11%. See more information on Glenmark Pharmaceuticals Limited dividends here
              What is Glenmark Pharmaceuticals Limited’s EPS estimate?
              Glenmark Pharmaceuticals Limited’s EPS estimate is 12.9.
                How many shares outstanding does Glenmark Pharmaceuticals Limited have?
                Glenmark Pharmaceuticals Limited has 282,200,800 shares outstanding.
                  What happened to Glenmark Pharmaceuticals Limited’s price movement after its last earnings report?
                  Glenmark Pharmaceuticals Limited reported an EPS of ₹10.1 in its last earnings report, missing expectations of ₹12.1. Following the earnings report the stock price went down -0.873%.
                    Which hedge fund is a major shareholder of Glenmark Pharmaceuticals Limited?
                    Currently, no hedge funds are holding shares in IN:GLENMARK

                    Company Description

                    Glenmark Pharmaceuticals Limited

                    Glenmark Pharmaceuticals Limited is a global pharmaceutical company headquartered in Mumbai, India. It operates in the healthcare sector, focusing on the research, development, manufacture, and marketing of branded and generic formulations. Glenmark is involved in the therapeutic areas of dermatology, oncology, respiratory, and cardiovascular diseases. The company is known for its robust pipeline of new chemical entities and biosimilars, and it has a significant presence in both emerging and developed markets.

                    GLENMARK Stock 12 Month Forecast

                    Average Price Target

                    ₹1,785.00
                    ▲(25.83%Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1262":"₹1,262","1393":"₹1,393","1524":"₹1,524","1655":"₹1,655","1786":"₹1,786"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1785,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.78K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1785,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.78K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1785,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.78K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1262,1393,1524,1655,1786],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1754.35,1756.7076923076922,1759.0653846153846,1761.423076923077,1763.7807692307692,1766.1384615384616,1768.496153846154,1770.853846153846,1773.2115384615383,1775.5692307692307,1777.926923076923,1780.2846153846153,1782.6423076923077,{"y":1785,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1754.35,1756.7076923076922,1759.0653846153846,1761.423076923077,1763.7807692307692,1766.1384615384616,1768.496153846154,1770.853846153846,1773.2115384615383,1775.5692307692307,1777.926923076923,1780.2846153846153,1782.6423076923077,{"y":1785,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1754.35,1756.7076923076922,1759.0653846153846,1761.423076923077,1763.7807692307692,1766.1384615384616,1768.496153846154,1770.853846153846,1773.2115384615383,1775.5692307692307,1777.926923076923,1780.2846153846153,1782.6423076923077,{"y":1785,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1263.89,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1436.34,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1685.58,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1666.7,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1693.3,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1550,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1614.05,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1452.5,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1278.75,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1278.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1380.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1496.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1754.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Alkem Laboratories Ltd.
                    Aurobindo Pharma Ltd
                    Biocon Limited
                    GlaxoSmithKline Pharmaceuticals Limited
                    Lupin Limited
                    Popular Stocks
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis